Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Microsoft

ServiceNow

AT&T

Tesla

Get ready. Tesla and Microsoft are among the tech titans that will report. Can they beat again?

5 Big Cap Earnings All Stars to Watch This Week

AutoZone

Fastenal

Home Depot

Winmark

According to the Good Companies Screen, a Premium value screen nested under the All-in-One Screener, five good companies that have outperformed the Standard & Poor's 500 index benchmark over the past 12 months include AutoZone Inc. ( AZO , Financial), Edwards Lifesciences Corp. ( EW , Financial), The Home Depot Inc. ( HD , Financial), Winmark Corp. ( WINA , Financial) and Fastenal Co. ( FAST , Financial).

5 Good Companies Outperforming the S&P 500

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Edwards Lifesciences (EW) Might Surprise This Earnings Season

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) to Report Q4 Results: Wall Street Expects Earnings Growth

IRVINE, Calif., Jan. 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022, and will host a conference call at 5:00 p.m.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022

There are medical emergency times when both a National Emergency and a Personal Emergency must have attention. People skills, facilities, time will be shared to preserve life. Easiest to picture is a failed heart valve replacement. Do or die. Now.

Edwards LifeSciences: When Even A Pandemonium Makes Room

Edwards Lifesciences (EW) closed at $118.26 in the latest trading session, marking a -1.83% move from the prior day.

Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P.

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).

Edwards Lifesciences (EW) at 52-Week High: What's Driving It?

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.

Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod

Mesa Laboratories

Sensus Healthcare

What History Shows Us About 2022 Market Returns

IRVINE, Calif., Dec. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation.

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Edwards (EW) States Long-Term Strategy, Provides 2022 View

IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months.

Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program

IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost.

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q3 2021 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.89% and -0.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Tops Q3 Earnings Estimates

Align Technology

Boston Scientific

Thermo Fisher Scientific

With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More

IRVINE, Calif., Oct. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2021 after the market closes on Wednesday, October 27, 2021, and will host a conference call at 5:00 p.m.

Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021

Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.

Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?

Michael Mussallem, Chairman And CEO at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Michael Mussallem exercised options to purchase 57,550 Edwards Lifesciences shares at prices ranging from ($0.00) to $21.76 per share for a total of $980,288 on October 1.

Notable Edwards Lifesciences Insider Trades $4.6M In Company Stock

Crown Castle International

Moody's

Sherwin-Williams

The GuruFocus business predictability rating ranks companies on a five-star scale, defining the more predictable companies as businesses whose revenue per share and Ebitda per share have been growing steadily and who have produced a strong long-term performance of their stock prices.

4 Stock Picks for a 'Buy and Hold' Approach

A few months back we discussed that Edward Lifesciences stock may continue to see higher levels after rising 10% in a month following the positive developments around Resilia tissue valves. EW stock has since rallied 16% to levels of $121 currently.

News for Edwards Lifesciences Stock (EW)